With 161 companies holding SEBI approvals worth ₹2.42 lakh crore, June's small OFS launches test whether the IPO window is truly reopening or just blinking.
Alpha Score of 43 reflects weak overall profile with moderate momentum, weak value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
India's primary market is emerging from a two-month freeze. Only two mainboard IPOs launched in April, and there were zero in May. June brings a handful of small offer-for-sale (OFS) deals, including Hexagon Nutrition and CMR Green Technologies, alongside ongoing SME issuances. The headline is a revival, yet the real question is whether these small tests can unlock a pipeline of 161 approved issuers waiting to raise about ₹2.42 lakh crore.
The June mainboard calendar features two OFS structures. Hexagon Nutrition will open an offer worth about ₹139 crore on June 5. CMR Green Technologies follows with a ₹630-crore OFS during June 3–5. Both are pure secondary sales, meaning no fresh capital flows to the companies. In the SME segment, issuers such as Merritronix, Liotech Industries, Vahh Chemicals, and Genxai Analytics are scheduled.
The combined mainboard size is roughly ₹769 crore. That is modest relative to the pipeline, yet these deals carry a disproportionate signalling weight.
The simple read: the calendar is no longer empty. Issuers are testing the waters.
The better market read: OFS structures keep execution risk low because there is no primary capital at stake, and the selling shareholders are often existing investors. If both deals clear at or near the price band, it signals that investors are willing to deploy capital into known names at reasonable valuations. If either undersubscribes or faces price cuts, it confirms that the window remains shut for larger, dilutive offerings.
While the mainboard froze in May, SME issuances continued. Companies such as SMR Jewels, M R Maniveni Foods, Yaashvi Jewellers, Rajnandini Fashion India, and Aureate Tradde are lined up for June. SME activity is a low-signal indicator for the mainboard because the investor base, regulatory scrutiny, and liquidity profile are entirely different. A busy SME calendar does not predict a busy mainboard one. However–wait, the constraint says no starting sentence with "However." So restructure: A freeze in SME issuance would signal a generalised risk-off posture that would also freeze the mainboard. That cross-signal is the only link worth watching.
According to Prime Database, 161 companies with valid SEBI approvals and an estimated issue size of about ₹2.42 lakh crore (roughly $29 billion) are awaiting launch. Another 74 companies seeking to raise about ₹1.53 lakh crore are awaiting regulatory clearance.
The list of large approved issuers includes:
Beyond the approved pipeline, marquee names such as Reliance Jio Platforms, the National Stock Exchange, Zepto, and SBI Mutual Fund are in the IPO pipeline without SEBI approvals yet.
The ₹2.42 lakh crore backlog is the most important metric for this market. If only a few small OFS deals clear in June, the backlog grows rather than shrinks. That puts upward pressure on valuation expectations and pricing discipline.
Issuers face a trade-off. Delaying means incurring additional costs to update financial disclosures and regulatory filings. Some may choose to launch in June or July to avoid those expenses, even if market conditions are not ideal. This creates a forced pipeline of deals that could test weak demand.
On the investor side, underwriters will bring the strongest stories first – consumption-led themes, financial services, and differentiated manufacturing. Weaker stories will be delayed further, creating a survivorship bias in the visible calendar. The June deals are likely the cream of the pipeline.
The two-month lull was driven by three factors: geopolitical tensions, market volatility, and valuation concerns. These forces have not disappeared.
A stabilisation in sentiment could unlock a stronger second half of FY27, according to market participants. The June–July window is therefore a proving ground. If it works, the approved pipeline will begin to de-risk. If it stalls, the next window may not open until after the Union Budget cycle.
The next four weeks provide a clear risk event to watch. The small June deals are not the endgame – they are a liquidity test. A successful test could trigger a wave of follow-on filings. A failed test would confirm that the ₹2.42 lakh crore backlog will stay frozen for months.
Practical rule: if CMR Green Technologies and Hexagon Nutrition clear without drama, start watching the big approved names for announcement dates. If either deal struggles, expect more deferrals rather than launches. For broader context on how primary market activity interacts with secondary liquidity and sector rotation, see our stock market analysis. Traders evaluating platforms for IPO participation can review our list of best stock brokers.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.